You are here: Home ยป Archives for board of directors

KFSH&RC begrüßt Dr. Björn Zoéga als neuen stellvertretenden CEO

RIAD, Saudi–Arabien, April 03, 2024 (GLOBE NEWSWIRE) — Das King Faisal Specialist Hospital and Research Centre (KFSH&RC) freut sich, die Ernennung von Dr. Björn Zoéga zum stellvertretenden Chief Executive Officer (CEO) mit Wirkung vom 1. April 2024 bekanntzugeben. Mit dieser strategischen Ernennung möchte das KFSH&RC seinem Bestreben, eine weltweit führende Gesundheitseinrichtung zu werden, zusätzlichen Antrieb geben, indem es die bemerkenswerte Karriere von Dr. Zoéga und seine nachgewiesene Führungserfahrung in hochrangigen medizinischen Einrichtungen nutzt.

Als ehemaliger CEO des international renommierten Karolinska–Universitätskrankenhauses in Schweden spielte Dr. Zoéga eine entscheidende Rolle bei der Aufrechterhaltung der hohen Standards der Einrichtung und ihrer weltweiten Anerkennung als zweitbestes Krankenhaus in Europa und siebtbestes weltweit laut der von Newsweek herausgegebenen Rangliste der besten Krankenhäuser der Welt 2024. Seine Zeit im Karolinska–Krankenhaus war von innovativen Strategien und Spitzenleistungen in der Gesundheitsversorgung geprägt, die er im KFSH&RC weiter ausbauen möchte.

Dr. Zoéga bringt jahrzehntelange Erfahrung im Management des Gesundheitswesens und im klinischen Bereich in das KFSH&RC ein, nachdem er als CEO des Nationalen Universitätskrankenhauses von Island und des Stockholmer Wirbelsäulenzentrums an der Spitze der Einrichtungen stand. Sein Wissens– und Erfahrungsschatz in Forschung und Lehre, den er sich als früherer Präsident und Verwaltungsratsvorsitzender der EU–Gesellschaft für Halswirbelsäulenforschung und als Vorsitzender des wissenschaftlichen Beirats von Alvotech aneignen konnte, stellen eine zusätzliche Bereicherung dar.

In seiner Funktion als stellvertretender CEO wird Dr. Zoéga die Bereiche Gesundheitsversorgung sowie Forschung und Innovation des KFSH&RC leiten und damit das Engagement des Krankenhauses für die Integration weltweit bewährter Praktiken im Gesundheitswesen und die Förderung modernster medizinischer Forschung und Technologie fortsetzen.

Das KFSH&RC lädt die Gemeinschaft, Partner und Interessengruppen ein, Dr. Björn Zoéga willkommen zu heißen, und freut sich auf ein vielversprechendes neues Kapitel in der Gesundheitsversorgung, das eine bessere und gesündere Zukunft für alle fördern soll.

Für weitere Informationen kontaktieren Sie bitte:

Essam Al–Zahrani, Media Affairs Acting Head, 0555254429

Abdullah Al–Awn, Senior Media Editor, 0556294232

Ein Foto zu dieser Mitteilung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/6a2fb3b5–9219–4e72–82fd–8f093f22996e


GLOBENEWSWIRE (Distribution ID 9084058)

Le KFSH&RC accueille le Dr Björn Zoëga en tant que nouveau directeur général adjoint

RIYAD, Arabie saoudite, 03 avr. 2024 (GLOBE NEWSWIRE) — Le King Faisal Specialist Hospital and Research Centre (KFSH&RC) est fier d’annoncer la nomination du Dr Björn Zoëga au poste de directeur général adjoint, à compter du 1er avril 2024. Cette décision stratégique vise à accélérer l’aspiration du KFSH&RC à devenir un établissement de soins de santé de premier plan sur la scène mondiale, en s’appuyant sur la carrière remarquable du Dr Zoëga et ses antécédents avérés en matière de leadership dans des établissements médicaux de premier plan.

En tant qu’ancien directeur général de l’hôpital universitaire Karolinska de Suède, de renommée internationale, le Dr Zoëga a joué un rôle essentiel dans le maintien des normes élevées de l’établissement et de sa reconnaissance mondiale en tant que deuxième hôpital le mieux classé parmi les hôpitaux européens et septième au niveau mondial selon le classement de Newsweek des meilleurs hôpitaux du monde en 2024. Son administration à Karolinska a été marquée par des stratégies innovantes et l’excellence en termes de prestations de santé, autant d’éléments qu’il se propose d’enrichir au sein du KFSH&RC.

Le Dr Zoëga apporte au KFSH&RC des décennies d’expérience en gestion des soins de santé et d’expertise clinique, après avoir dirigé les opérations en tant que directeur général de l’hôpital universitaire national d’Islande et du Stockholm Spine Center. Son expérience et ses compétences en matière de recherche et d’éducation sont également inestimables, compte tenu de ses anciens rôles de président et de président du conseil d’administration de l’EU–Cervical Spine Research Society et de président du Conseil consultatif scientifique d’Alvotech.

En tant que directeur général adjoint, le Dr Zoëga dirigera les groupes de prestation de soins de santé et de recherche et d’innovation du KFSH&RC, conformément à l’engagement de l’hôpital d’intégrer les meilleures pratiques mondiales en matière de soins de santé et de poursuivre la recherche médicale et la technologie de pointe.

Le KFSH&RC invite la communauté, les partenaires et les parties prenantes à accueillir le Dr Björn Zoëga, tandis que l’établissement entame un nouveau chapitre prometteur dans le domaine des soins de santé, en s’engageant à favoriser un avenir plus brillant et plus sain pour tous.

Pour plus d’informations, veuillez contacter :

M. Essam Al–Zahrani, chef par intérim des affaires médiatiques, 0555254429

M. Abdullah Al–Awn, rédacteur en chef des médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/6a2fb3b5–9219–4e72–82fd–8f093f22996e


GLOBENEWSWIRE (Distribution ID 9084058)

KFSH&RC Dá Boas-Vindas ao Novo CEO Adjunto Dr. Björn Zoéga

RIADE, Arábia Saudita, April 03, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) tem o orgulho de anunciar a nomeação do Novo CEO Adjunto Dr. Björn Zoéga em 1 de abril de 2024. Esse movimento estratégico deve acelerar o objetivo da KFSH&RC de se tornar uma instituição de saúde líder no cenário global, alavancando a notável carreira e o histórico comprovado de liderança do Dr. Zoéga em instituições médicas de primeira linha.

Como ex–CEO do internacionalmente renomado Karolinska University Hospital, na Suécia, o Dr. Zoéga desempenhou um papel fundamental na defesa dos altos padrões e do reconhecimento global da instituição como o segundo mais bem avaliado entre os hospitais europeus e o sétimo melhor do mundo, de acordo com o ranking da Newsweek dos Melhores Hospitais do Mundo 2024. Sua administração da Karolinska foi marcada por estratégias inovadoras e excelência na prestação de cuidados de saúde – tudo o que ele pretende aprimorar no KFSH&RC.

No KFSH&RC, o Dr. Zoéga irá utilizar suas décadas de gestão de saúde e experiência clínica, na liderança em operações como CEO do National University Hospital da Islândia e do Stockholm Spine Center. Sua experiência e competência em pesquisa e educação também são inestimáveis, como nas suas funções anteriores na qualidade de Presidente e Presidente do Conselho da Sociedade de Pesquisa da Coluna Cervical da UE e Presidente do Conselho Consultivo Científico da Alvotech.

Como CEO Adjunto, o Dr. Zoéga atuará como líder dos grupos de prestação de cuidados de saúde e pesquisa e inovação do KFSH&RC, seguindo o compromisso do hospital em integrar as melhores práticas globais em cuidados de saúde e buscar pesquisas e tecnologias médicas de ponta.

O KFSH&RC estende seu convite à comunidade, parceiros e partes interessadas a dar as boas–vindas ao Dr. Björn Zoéga, nesse novo capítulo promissor que a instituição embarca na área da saúde, comprometida em promover um futuro mais brilhante e saudável para todos.

Para mais informações, contate:

Sr. Essam Al–Zahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Al–Awn, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/6a2fb3b5–9219–4e72–82fd–8f093f22996e 


GLOBENEWSWIRE (Distribution ID 9084058)

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC's aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga's notable career and proven track record of leadership in top–tier medical institutions.

As the former CEO of the internationally renowned Karolinska University Hospital in Sweden, Dr. Zoéga played a pivotal role in upholding the institution’s high standards and global recognition as the second highest rated among European hospitals and seventh best worldwide according to Newsweek’s ranking of the World’s Best Hospitals 2024. His administration at Karolinska was marked by innovative strategies and excellence in healthcare delivery—all which he is posed to enrich within KFSH&RC.

Dr. Zoégabrings decades of healthcare management and clinical expertise to KFSH&RC, having spearheaded operations as CEO of the National University Hospital of Iceland and the Stockholm Spine Center. His experience and faculties in research and education are also invaluable, given his former roles as President and Board Chairman of the EU–Cervical Spine Research Society and Chairman of the Scientific Advisory Board of Alvotech.

As Deputy CEO, Dr. Zoéga will serve as chief lead of KFSH&RC’s healthcare delivery and research and innovation groups, following on the hospital’s commitment to integrating global best practices in healthcare and pursuing cutting–edge medical research and technology.

KFSH&RC extends its invitation to the community, partners, and stakeholders to welcome Dr. Björn Zoéga, as the institution embarks on a promising new chapter in healthcare, committed to fostering a brighter and healthier future for all.

For more information, please contact:

Mr. Essam Al–Zahrani, Media Affairs Acting Head, 0555254429

Mr. Abdullah Al–Awn, Senior Media Editor, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a2fb3b5–9219–4e72–82fd–8f093f22996e 


GLOBENEWSWIRE (Distribution ID 9083029)

Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership

TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 25, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd (Nasdaq: CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the appointment of David Gee as Chief Marketing Officer (CMO). Mr. Gee brings more than 25 years of global sales and marketing expertise and will serve as a member of Cellebrite’s executive leadership team, reporting directly to CEO Yossi Carmil. He will oversee Cellebrite’s global marketing strategy and execution to help the Company capitalize on the major growth opportunities ahead in the digital investigations marketplace.

Mr. Gee joins Cellebrite as digital crimes escalate exponentially, and criminal activities become more sophisticated, requiring law enforcement and enterprises to apply more advanced tools to fully capture, manage and analyze all the digital evidence at their disposal. Cellebrite’s end–to–end Case–to–Closure (C2C) platform helps investigative teams in both public and private sectors reach time–to–evidence quicker and close cases faster, smarter and more defensibly than ever before.

“Cellebrite stands on the precipice of an unparalleled opportunity. As we forge ahead, scaling our extraordinary growth, we welcome aboard David Gee, a strategic marketing luminary,” said Yossi Carmil, Cellebrite CEO. “His seasoned expertise will propel our global expansion. David embodies our vision and champions the ethical and responsible use of technology, recognizing its power to safeguard our world. Together, we’ll redefine what’s possible.”

As a seasoned industry veteran, Mr. Gee brings a wealth of experience to his role as CMO. His previous roles have left indelible marks, and now he’s ready to propel Cellebrite to new heights. Most recently, he served as CMO at Coherent Inc. where he digitally transformed the business and was part of the management team that doubled the market capitalization within two years. Previously, David was CMO at Imperva, Zuora and Infoblox and held senior marketing and operational roles at Hewlett Packard, Yahoo!, Sun Microsystems and IBM.

“It is rare to find an opportunity that fits my personal values, while also aligning with my skill set. I am thrilled to join Cellebrite and become part of such an important, mission–based business,” said Mr. Gee. “Cellebrite’s achievements to date are inspiring, and the opportunities ahead to further accelerate justice are exciting. I look forward to working with my new colleagues as we focus on executing the programs, campaigns, and initiatives that will broaden market awareness and adoption of the Company’s innovative digital investigative solutions.”

To learn more about Cellebrite and its Case–to–Closure Platform, please visit www.cellebrite.com.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, the following: helping our team further expand our business around the world; and executing the programs, campaigns and initiatives that will broaden market awareness of the Company’s innovative digital investigative solutions, fortify and expand our customer relationships globally, increase our market leadership and achieve our business objectives. Such forward–looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on March 21, 2024 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 

Victor Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 

Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd321307–8ce5–4237–86b7–324ddbd27380


GLOBENEWSWIRE (Distribution ID 9078473)

Phosphorus تصدر قرارًا بتعيين Osama AlZoubi نائباً للرئيس الإقليمي للشركة في المملكة العربية السعودية والشرق الأوسط

ناشفيل، تينيسي, March 14, 2024 (GLOBE NEWSWIRE) — أعلنت اليوم شركة Phosphorus Cybersecurity Inc.‎، الرائدة في مجال الإدارة الموحدة للعمليات الأمنية القائمة على الأساليب الاستباقية لإنترنت الأشياء الممتد (xIoT)، عن تعيين Osama AlZoubi نائبًا للرئيس الإقليمي للشركة في المملكة العربية السعودية والشرق الأوسط. سوف يشرف AlZoubi خلال توليه مهام منصبه الجديد على نمو شركة Phosphorus وتطورها في المملكة العربية السعودية والشرق الأوسط، حيث تقوم الشركة بتوسيع تواجدها في المنطقة من خلال منصة حماية النظام السيبراني المادي (CPS) الأفضل في فئتها التي تستطيع الكشف عن النطاق الكامل لأجهزة إنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية فضلاً عن معالجة هذا النطاق ومراقبته وإدارته.

تشهد منطقة المملكة العربية السعودية والشرق الأوسط تقدمًا تكنولوجيًا كبيرًا، لا سيما في مجالات الطاقة والتصنيع الذكي والتنمية الحضرية نظرًا لكونها واحدة من أسرع المناطق الاقتصادية نموًا في العالم. هذا وتقود المملكة العربية السعودية قاطرة تحول كبير في المنطقة وذلك من خلال رؤية المملكة 2030 – حيث يتم تنفيذ العديد من المشاريع الضخمة والعملاقة مثل نيوم، وحديقة الملك سلمان، والدرعية بالإضافة إلى المربعة، ومشروع البحر الأحمر، والقدية. وفي ضوء ذلك، يتطلب التطور والتكامل السريع للأنظمة السيبرانية المادية المتقدمة في المنطقة توفير قدرات أمنية تتسم بمزيد من القوة لحماية أجهزة إنترنت الأشياء والتكنولوجيا التشغيلية الحساسة من التعرض للتهديدات المتزايدة جراء الهجمات السيبرانية. وعلى هذا النحو، سوف يحظى AlZoubi بدور فاعل في قيادة جهود Phosphorus لمساعدة الشركات العامة والخاصة في المنطقة على حد سواء على تحقيق أعلى مستويات الأمن السيبراني الاستباقي لجميع مباني إنترنت الأشياء الممتد الخاصة بها، بما في ذلك الأصول الأكثر حساسية للمهام والأصول الهامة للحياة.

وفي هذا السياق صرح Chris Rouland، الرئيس التنفيذي لشركة Phosphorus قائلاً “يتسم Osama بالبراعة في مجال الكمبيوتر علاوة على أنه قد شغل في السابق منصب رئيس قسم التكنولوجيا لدى شركة Cisco في منطقة الشرق الأوسط وأفريقيا، فضلاً عن أنه قد ساعد في تصميم العديد من الشبكات التي نعمل على تأمينها. إن ما يتمتع به من قدر كبير من المعرفة فضلاً عن خبرته الواسعة ستجعل منه إضافة هائلة لشركتنا وفريق القيادة العليا لدينا”. “يحظى الأمن السيبراني بأهمية بالغة في المملكة العربية السعودية التي تشهد معدلات نمو سريعة وفي جميع أنحاء منطقة الشرق الأوسط، حيث تضخ المزيد من الدول استثمارات في التقنيات المتقدمة، مثل المدن الذكية. وفي ذات السياق، تتطلب هذه الأصول الهامة التي تتعلق بإنترنت الأشياء والتكنولوجيا التشغيلية مستوى جديدًا من الحماية لا تستطيع الحلول الأمنية التقليدية الوفاء به. وسيحظى Osama بدور هام في توسيع نطاق عمليات منصة إنترنت الأشياء الممتد الخاصة بنا عبر هذه المنطقة لضمان حصول عملائنا على أعلى مستوى من الحماية الاستباقية للأنظمة السيبرانية المادية.”

وعلى الجانب الآخر، صرح السيد AlZoubi قائلاً “تمثل شركة Phosphorus إحدى الشركات الرائدة التي تتسم بالابتكار في مجال العمليات الأمنية حيث تتمتع بإمكانات هائلة على الصعيدين المحلي والدولي. “كما أنها تتفرد بالقدرة على اكتشاف النطاق الكامل لأصول إنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية التي دائمًا ما تكون عرضة للهجمات المستمرة فضلاً عن معالجة هذا النطاق ومراقبته وإدارته بشكل استباقي. وينطبق هذا الأمر على المملكة العربية السعودية ومنطقة الشرق الأوسط وأفريقيا بشكل خاص، حيث لا يؤدي تطور التكنولوجيا المتقدمة إلى إيجاد فرص اقتصادية هائلة فحسب، بل يصل الأمر إلى احتمالية التعرض للتعطل الناجم عن برامج الفدية والهجمات المادية السيبرانية. أشعر بحماسة بالغة بانضمامي إلى هذه الشركة التي تحظى بالابتكار وإنني لأتطلع إلى تسريع وتيرة نموها بالمنطقة.

يتسم AlZoubi بكونه أحد رواد التكنولوجيا والأعمال، ويتمتع بخبرات عريضة تربو على 25 عامًا في مجال تكنولوجيا المعلومات والاتصالات. ومن بين أبرز المجالات المحورية التي يبرع بها يأتي الأمن السيبراني والذكاء الاصطناعي وإنترنت الأشياء فضلاً عن مراكز البيانات والبرمجيات والبنية التحتية. وعلى مدى مسيرته المهنية، حظي AlZoubi بدور فاعل في العديد من مبادرات البحث والتطوير المتقدمة، بما في ذلك براءة اختراع لنظام إنترنت الأشياء اللاسلكي تحت الماء.

شغل AlZoubi العديد من المناصب القيادية على الصعيد الدولي قبل انضمامه إلى Phosphorus، حيث شغل مؤخرًا منصب رئيس قسم التكنولوجيا لدى شركة Cisco لمنطقة الشرق الأوسط وأفريقيا. كما تولى أيضًا قيادة فرق الهندسة وتصميم الأعمال، لدفع وتيرة التحول الرقمي عبر منطقة الشرق الأوسط وأفريقيا، مع قيادة مبادرات الرقمنة والابتكار ونمو الأعمال عبر القطاعين العام والخاص في المملكة العربية السعودية والشرق الأوسط وأفريقيا، وبالإضافة إلى ذلك فهو أيضًا مؤلف كتاب “The Digital Disruption”، وهو حاصل على براءة اختراع في مجال إنترنت الأشياء، كما أن له العديد من المنشورات في مجلة هارفارد بزنس ريفيو العربية. حصل AlZoubi على درجة بكالوريوس العلوم في هندسة الكمبيوتر من جامعة إلينوي في شيكاغو بالإضافة إلى ماجستير العلوم في علوم الكمبيوتر من معهد إلينوي للتكنولوجيا في شيكاغو.

تتسم منصة Phosphorus المعترف بها من جانب Gartner وهي منصة إدارة العمليات الأمنية الموحدة لإنترنت الأشياء الممتد بكونها منصة الحماية الوحيدة للنظام السيبراني المادي في القطاع حيث تغطي مجال الأمن والإدارة الكاملة لإنترنت الأشياء بشكل استباقي. ومن خلال قدرتها الفريدة على التواصل المباشر مع ما يزيد عن مليون طراز من الأجهزة (بما في ذلك أكثر من 600 مورد) بلغاتهم الأصلية، تمكن منصة Phosphorus جميع المؤسسات من اكتشاف أي أجهزة تتعلق بإنترنت الأشياء، والتكنولوجيا التشغيلية، وإنترنت الأشياء الطبية وتقويتها ومعالجتها وإدارتها على نحو آمن، بما في ذلك الأصول الأكثر حساسية للمهام والحياة.

للتعرف على المزيد من المعلومات حول شركة Phosphorus، يمكنكم زيارة الموقع الإلكتروني www.phosphorus.io أو متابعتنا في الفعاليات القادمة، مثل RSAC، وBlack Hat، وDEF CON.

نبذة حول PHOSPHORUS

Phosphorus Cybersecurity®‎ هي إحدى المنصات الرائدة في مجال حماية النظام السيبراني المادي حيث تقدم نهجًا استباقيًا لإدارة العملية الأمنية ومنع حدوث الاختراقات التي يتعرض لها إنترنت الأشياء، وتكنولوجيا التشغيل، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية. وقد تم تصميم هذه المنصة للتعرف على الأنظمة السيبرانية المادية سريعة النمو وغير المعروفة وغير الخاضعة للرقابة وتأمينها في نطاق إنترنت الأشياء الممتد، هذا وتوفر منصة إدارة العمليات الأمنية الموحدة الخاصة بإنترنت الأشياء الممتد إدارة أمنية لا مثيل لها فضلاً عن منع حدوث الاختراقات عبر جميع القطاعات – مما يجعلها توفر دقة عالية في الاكتشاف وتقييم المخاطر، والتقوية والمعالجة الاستباقية بالإضافة إلى المراقبة والإدارة المستمرة. ومن خلال الاكتشاف الذكي الفعال لإنترنت الأشياء الممتد وتقييم المخاطر الحاصل على براءة اختراع، تقوم Phosphorus بأتمتة عملية تخفيف ومعالجة أهم نقاط الضعف في الأجهزة الخاصة بإنترنت الأشياء، وتكنولوجيا التشغيل، وإنترنت الأشياء الصناعية، وإنترنت الأشياء الطبية – بما في ذلك مخزون الأصول غير المعروف وغير الدقيق، وبيانات الاعتماد الافتراضية فضلاً عن البرمجيات الثابتة القديمة والضعيفة، والتكوينات التي تتسم بالخطورة، والأجهزة المحظورة ومنتهية الصلاحية بالإضافة إلى الشهادات منتهية الصلاحية أو الموقعة ذاتيًا. يمكنكم متابعة Phosphorus عبر LinkedIn، Twitter، Threads، بالإضافة إلى YouTube، كما يمكن التعرف على المزيد من المعلومات عبر الموقع الإلكتروني www.phosphorus.io 

مسؤول الاتصالات الإعلامية:


GLOBENEWSWIRE (Distribution ID 9063443)

Phosphorus Appoints Osama AlZoubi as Regional Vice President of Saudi Arabia and Middle East

NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) — Phosphorus Cybersecurity Inc., the leading provider of unified, prevention–based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East. In his new role, AlZoubi will oversee Phosphorus’ growth and development throughout the Kingdom of Saudi Arabia and the Middle East, as the company expands its presence in the region with its best–of–breed Cyber–Physical System (CPS) Protection Platform that discovers, remediates, monitors, and manages the full scope of IoT, OT, IIoT, and IoMT devices.

As one of the world’s fastest growing economic regions, Saudi Arabia and the Middle East are experiencing significant technological progress, particularly in energy, smart manufacturing, and urban development. Saudi Arabia is also spearheading a monumental transformation in the region with its Vision 2030 – with mega and giga projects like NEOM, King Salman Park, Diriyah, Murabba, the Red Sea Project, and Qiddiya. The region’s rapid development and integration of advanced Cyber–Physical Systems requires more robust security capabilities to protect sensitive IoT and OT devices from the growing threat of cyber attacks. AlZoubi will play a critical role in leading Phosphorus’ efforts to assist the region’s public and private enterprises in achieving the highest level of proactive cybersecurity for their entire xIoT estates, including the most sensitive mission–critical and life–critical assets.

“Osama is an accomplished computer scientist and former CTO of Cisco Middle East and Africa who helped build many of the networks we work to secure. His knowledge and experience will make him a tremendous asset to our organization and senior leadership team,” said Chris Rouland, CEO of Phosphorus. “Cybersecurity is critically important in fast–developing Saudi Arabia, and across the Middle East region, as more countries invest in advanced technologies, such as smart cities. These critical IoT and OT assets require a new level of protection that traditional security solutions simply cannot provide. Osama will play a crucial role in expanding our xIoT platform across this region to ensure our customers have the highest level of proactive protection for their Cyber–Physical Systems.”

“Phosphorus is a groundbreaking and disruptive security company with remarkable potential in the region and throughout the world,” said AlZoubi. “Only Phosphorus has the capability to proactively discover, remediate, monitor, and manage the full range of IoT, OT, IIoT, and IoMT assets that represent an ever–expanding attack surface. This is especially true in the Kingdom of Saudi Arabia, and throughout the Middle East and Africa, where high–tech development is not only creating massive economic opportunity, but also the potential for disruption from ransomware and cyber–physical attacks. I am excited to join this innovative company and I look forward to accelerating its growth in the region.”

AlZoubi is a seasoned technology and business leader with over 25 years of extensive experience in information and communications technology (ICT). His expertise encompasses pivotal domains such as cybersecurity, artificial intelligence (AI), IoT, data centers (DC), software (SW), and infrastructure. Throughout his career, he has actively engaged in cutting–edge research and development initiatives, including a patent for a wireless underwater IoT system.

Prior to joining Phosphorus, AlZoubi held multiple global leadership roles and most recently served as Chief Technology Officer (CTO) for Cisco in the Middle East and Africa. AlZoubi led the Engineering and Business Architecture teams, to drive Digital Transformation across the MEA region, while driving the digitization initiatives, innovation, and business growth across the private and public sector in Saudi Arabia, the Middle East, and Africa. AlZoubi is also the author of “The Digital Disruption”, he holds a patent in the IoT field, and he has multiple publications in Harvard Business Review Arabia. He has a Bachelor of Science degree in Computer Engineering from the University of Illinois at Chicago (UIC), and a Master of Science in Computer Science from the Illinois Institute of Technology (IIT) in Chicago.

Phosphorus’ Gartner–recognized Unified xIoT Security Management Platform is the industry’s only CPS Protection Platform proactively covering the entire security and management lifecycle for xIoT. Through its unique ability to directly communicate with over one million device models (including over 600 vendors) in their native languages, Phosphorus’ platform empowers all organizations to safely discover, harden, remediate, and manage any IoT/OT/IoMT device, including the most sensitive mission–critical and life–critical assets.

For more information about Phosphorus, visit www.phosphorus.io, or see us at upcoming conferences, such as RSAC, Black Hat, and DEF CON.

ABOUT PHOSPHORUS

Phosphorus Cybersecurity® is the leading CPS Protection Platform delivering a proactive approach to security management and breach prevention for the exploding IoT, OT, IIoT, and IoMT attack surface. Designed to find and secure the rapidly growing, unknown, and often unmonitored world of Cyber–Physical Systems across the xTended Internet of Things landscape, our Unified xIoT Security Management Platform provides unmatched security management and breach prevention across every industry vertical—delivering high–fidelity discovery and risk assessment, proactive hardening and remediation, and continuous monitoring and management. With patented xIoT Intelligent Active Discovery and risk assessment, Phosphorus automates the mitigation and remediation of the most significant IoT, OT, IIoT, and IoMT device vulnerabilities – including unknown and inaccurate asset inventory, default credentials, out–of–date and vulnerable firmware, risky configurations, banned and end–of–life devices, and expired or self–signed certificates. Follow Phosphorus on LinkedIn, Twitter, Threads, and YouTube, and learn more at www.phosphorus.io 


GLOBENEWSWIRE (Distribution ID 9062687)

Dentsu Appoints Shirli Zelcer to Chief Data and Technology Officer

TOKYO, March 07, 2024 (GLOBE NEWSWIRE) — Dentsu (brand: dentsu; Head Office: Dentsu Group Inc.; Location: Tokyo; Representative: President and Global CEO Hiroshi Igarashi) today announced the appointment of Shirli Zelcer as Chief Data and Technology Officer (CDTO), sitting on dentsu’s Group Management Team. In this role, Zelcer will be responsible for all of dentsu’s client–facing data–driven, analytics and technology–enabled products and platforms, driving innovation and sustainable growth for clients.

Dentsu also announced today that Steve Simpson has been appointed as President, Data, Audiences and Technology, dentsu and Shiva Vannavada as President, Data and Technology Solutions, dentsu. Simpson will join the Global Media Practice leadership team to support the development of a winning Media Practice community that delivers continued excellence in its offering to clients, driving client growth and transformation. In his newly created role, Simpson will be responsible for the strategic planning and delivery of a globally–scaled, data–driven and technology–enabled audience platform that drives growth for clients, while Vannavada will focus on creating synergies across product and platforms, AI innovation, analytics and across Dentsu Global Services (DGS).  

Zelcer brings over 20 years of experience in analytics and insights, business advisory and organizational design, AI and data science, and cloud and marketing technologies. She was most recently the Global Head of Analytics and Technology at Merkle, where she led a global division of over 5,600 practitioners across the Americas, EMEA, and APAC. In her new role at dentsu, Zelcer will be responsible to innovate the vision, roadmap, development and commercial impact of dentsu's data and tech strategy across our three core practice areas: Media, CXM and Creative, working closer with Practice leads and Jean Lin, Global President – Global Practices, dentsu. The role will lead a newly formed team brought together from these Practice areas to drive consistency, interoperability and ultimately to deliver growth to dentsu’s clients through more unified capabilities. 

Joining from Publicis, in his new role, Simpson will lead a global team of experts from across data management, identity, personalization, media activation and dynamic creative production, and partner with dentsu’s global products and platforms team to integrate and scale the platform across dentsu’s Global Practices.

Simpson will also be accountable for evolving dentsu’s global media delivery platform. Enabled by programmatic media delivery, enriched with 1st, 2nd and 3rd party data, it will leverage dentsu’s leading Merkury products suite to drive client competitiveness. 

Having previously served as Global Chief Product and Technology Officer, dentsu Solutions, Vannavada’s expanded responsibilities as President, Data and Technology Solutions will include driving cross–practice and product collaboration, nurturing dentsu’s AI Connective community and leading his team to contribute to tech–enabled solutions and strategy. 

“Innovation across data and technology are two of dentsu’s most critical points of differentiation, having led the market for many years in the development, adoption and application of proprietary platforms which give our clients the edge,” said Hiroshi Igarashi, President and Global CEO, dentsu. “We are very proud to appoint Shirli, Steve and Shiva into these new strategic roles which bring together our efforts across the organization, honing our capabilities and ensuring that dentsu and our clients remain at the forefront of innovation.”

The leadership of the broader Data and Tech organization at dentsu includes: Head of Product, Matt Seeley, and Sunil Rao leading Analytics, and Peter Rogers leading Data Platforms. DGS will also now report into Zelcer’s Data and Technology structure and in turn, Zelcer will report into Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu. 

Quotes: 

“During her time at Merkle, Shirli brought together teams from around the world to collaborate on vital programs, ranging from data infrastructure implementation to advanced media mix modeling, personalization strategies and the development of bespoke AI solutions,” commented Michael Komasinski, CEO, dentsu Americas & Global President – Data & Technology, dentsu. “With her vast experience of successfully partnering with clients, alongside a proven ability to solve business challenges with cutting–edge technology solutions, I'm truly excited to see the impact that Shirli will have in her new expanded global role at dentsu.” 

“It is a very exciting prospect to move into this new role at a time when not only is dentsu at a pivotal moment in its history, but data and technology have never evolved at a faster pace,” remarked Shirli Zelcer, Chief Data and Technology Officer, dentsu. “As a group, we have already made some big moves into AI over the last few years, but I truly see the combination of AI with dentsu proprietary and partner technologies as a major differentiator for our clients. I’m looking forward to broadening the impact I can have across dentsu and working closely with the talented leaders and teams across our tech community.”

Steve Simpson, President, Data, Audiences and Technology, dentsu, said: “I am thrilled to join dentsu at this exciting time of transformation and innovation. Data and technology are at the heart of the media industry and the integrated opportunity across Practices at dentsu in vast. I look forward to working with the talented teams throughout dentsu to build a world–class platform that will deliver value and innovation for our clients, helping them achieve their business goals.” 

Shiva Vannavada, President, Data and Technology Solutions, dentsu, commented: “Since I began my journey at dentsu, we have been actively planning our future with AI and I am excited to take on this new expanded remit as we enter into what will undoubtedly be a transformational year for AI and the products and solutions we build using it. At dentsu, we don’t consider AI as a standalone technology, it is part of the fabric of our data, technology and product capabilities, ingrained into every practice and present in every agency brand. This makes us naturally more collaborative, more integrated and faster to market for our clients, and I look forward to working with teams across dentsu to break new ground in what is possible across data and tech for our clients.” 

About dentsu  

Dentsu is the network designed for what’s next, helping clients predict and plan for disruptive future opportunities and create new paths to growth in the sustainable economy. Taking a people–centered approach to business transformation, we use insights to connect brand, content, commerce and experience, underpinned by modern creativity. As part of Dentsu Group Inc. (Tokyo: 4324; ISIN: JP3551520004), we are headquartered in Tokyo, Japan, and our 71,000–strong employee base of dedicated professionals work across four regions (Japan, Americas, EMEA and APAC). Dentsu combines Japanese innovation with a diverse, global perspective to drive client growth and to shape society.

https://www.dentsu.com/  
https://www.group.dentsu.com/en/ 

Contact:

Matt Cross
Phone: +442074306319
Email: matt.cross@dentsu.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf533a57–ac1f–4ad2–87e5–340b90ec6957


GLOBENEWSWIRE (Distribution ID 1000927842)

Zenas BioPharma beruft Patricia Allen in den Verwaltungsrat

WALTHAM, Massachusetts, March 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, ein weltweit tätiges Biopharmazieunternehmen, dessen Ziel eine führende Rolle in der Entwicklung und Kommerzialisierung von Entzündungs– und Immunologietherapien ist, gab heute die Ernennung von Patricia Allen in den Verwaltungsrat des Unternehmens bekannt, in dem sie auch als Vorsitzende des Prüfungsausschusses fungieren wird. Frau Allen wird sich mit mehr als 20 Jahren Erfahrung in den Bereichen Finanzen, Anlegerbeziehungen, Geschäftsentwicklung, Personalwesen, Betrieb und IT in globalen börsennotierten und privaten Biotechnologieunternehmen in den Verwaltungsrat von Zenas einbringen.

„Wir freuen uns, Frau Allen in unserem Verwaltungsrat begrüßen zu dürfen“, so Lonnie Moulder, Gründer und Verwaltungsratsvorsitzender von Zenas BioPharma. „Sie hat erfolgreich organisationsübergreifende Funktionen geleitet und war im Verwaltungsrat von privaten und börsennotierten globalen Biotechnologieunternehmen tätig. Wir freuen uns auf Frau Allens Beitrag zur nächsten Wachstumsphase von Zenas, während wir unsere Mission vorantreiben, transformative immunologische Therapien für Patienten zu entwickeln und zu vermarkten, die diese dringend benötigen.“

„Ich freue mich auf die Zusammenarbeit mit dem erfahrenen Team von Zenas und dem Verwaltungsrat, die durch disziplinierte Umsetzung der Pipeline und Geschäftsentwicklung ein führendes, auf Entzündungen und Immunologie fokussiertes globales Biopharmazieunternehmen aufbauen“, so Frau Allen. „Dies ist eine aufregende Zeit für Zenas, da das Unternehmen aktuell versucht, mehrere Programme in der Klinik voranzutreiben, um letztendlich das Leben von Menschen mit Autoimmunkrankheiten zu verbessern.“

Frau Allen war zuletzt als Chief Financial Officer bei Vividion Therapeutics tätig, wo sie kürzlich ausschied. Während ihrer Zeit bei Vividion leitete sie das Fundraising und die Übernahme des Unternehmens durch die Bayer AG mit, während das Unternehmen wuchs und mehrere Programme in Richtung Klinik vorantrieb. Derzeit ist sie Mitglied des Verwaltungsrats und Vorsitzende des Prüfungsausschusses von Deciphera Pharmaceuticals, SwanBio Therapeutics und Anokion. Darüber hinaus war sie in der Vergangenheit Mitglied des Verwaltungsrats und Vorsitzende des Prüfungsausschusses von Inversago Pharma und Yumanity Therapeutics.

Vor ihrer Tätigkeit bei Vividion hielt Frau Allen die Position des Chief Financial Officer bei Zafgen, Inc. (jetzt Larimer Therapeutics) inne. Zuvor war sie Vice President of Finance and Treasurer, Principal Financial Officer bei Alnylam Pharmaceuticals, Inc. sowie Director of Finance bei Alkermes, Inc. und Wirtschaftsprüferin bei Deloitte & Touche, LLP. Sie besitzt einen B.S.–Abschluss in Betriebswirtschaft vom Bryant College.

Über Zenas BioPharma

Zenas BioPharma ist ein weltweit tätiges Biopharmazieunternehmen, das sich zum Ziel gesetzt hat, ein führendes Unternehmen in der Entwicklung und Vermarktung von entzündungs– und immunologieorientierten Therapien für dringend darauf angewiesene Patienten in aller Welt zu werden. Zenas verfügt über klinische Entwicklungskapazitäten und ist weltweit tätig, um ein Portfolio potenziell differenzierter Autoimmuntherapeutika in Bereichen mit hohem medizinischen Bedarf zu entwickeln. Wir nutzen die Erfahrung und die Fähigkeiten unseres Führungsteams und unsere etablierten Netzwerke in der Biopharmaziebranche, um Therapien zu entwickeln, die das Leben von Menschen mit Autoimmunerkrankungen und seltenen Krankheiten verbessern können. Für weitere Informationen über Zenas BioPharma besuchen Sie bitte www.zenasbio.com und folgen Sie uns auf X (früher Twitter) unter @ZenasBioPharma sowie LinkedIn.

Anleger– und Medienkontakt:
Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9059519)

Zenas BioPharma Nomeia Patricia Allen para o Conselho Diretor

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia, divulgou hoje a nomeação de Patricia Allen para o Conselho Diretor, onde atuará também como Presidente do Comitê de Auditoria. A Sra. Allen ingressa no Conselho Diretor da Zenas com mais de 20 anos de experiência liderando finanças, relações com investidores, desenvolvimento de negócios, recursos humanos, operações e TI em empresas globais públicas e privadas de biotecnologia.

“Estamos muito contentes com a vinda de Patty para o nosso Conselho Diretor”, disse Lonnie Moulder, Fundador e Diretor Executivo da Zenas BioPharma. “Ela liderou com sucesso funções interorganizacionais e atuou no conselho diretor de empresas privadas e públicas de biotecnologia global. Estamos prontos para as contribuições de Patty para a próxima fase do crescimento da Zenas, à medida que avançamos na nossa missão de desenvolver e comercializar terapias transformadoras baseadas em imunologia para pacientes necessitados.”

“Estou pronta para colaborar com a experiente equipe da Zenas e o Conselho Diretor, que estão ampliando uma empresa biofarmacêutica global líder em inflamação e imunologia por meio da execução disciplinada de pipeline e desenvolvimento de negócios”, disse a Sra. Allen. “A Zenas está muito empolgada com o progresso dos seus múltiplos programas clínicos que irão aprimorar as vidas das pessoas que sofrem de doenças autoimunes.”

Recentemente, a Sra. Allen atuou como Diretora Financeira da Vividion Therapeutics, de onde se aposentou recentemente. Na Vividion, ela co liderou a captação de recursos e a aquisição da empresa pela Bayer AG, durante o crescimento e avanço da empresa com vários programas em direção à clínica. Ela atua no conselho diretor e como presidente do comitê de auditoria da Deciphera Pharmaceuticals, SwanBio Therapeutics e Anokion, além de ser ex–membro do conselho e presidente do comitê de auditoria da Inversago Pharma e Yumanity Therapeutics.

Antes de ingressar na Zenas, a Sra. Allen atuou como Diretora Financeira da Zafgen, Inc. (atual Larimer Therapeutics). Anteriormente, ela foi Vice–Presidente de Finanças e Tesoureira, Diretora Financeira Principal da Alnylam Pharmaceuticals, Inc.; Diretora de Finanças da Alkermes, Inc.; e Auditora da Deloitte & Touche, LLP. Ela é formada em Administração de Empresas pelo Bryant College.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias voltadas para inflamações e imunologia para pacientes necessitados em todo o mundo. Com desenvolvimento clínico e operações globais, a Zenas está avançando um portfólio de terapêuticas autoimunes potencialmente diferenciadas em áreas de alta necessidade médica. Aproveitamos a experiência e a capacidade da nossa equipe de gestão executiva a das nossas existentes na indústria biofarmacêutica em busca do desenvolvimento de terapias que possam melhorar as vidas das pessoas com doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga–nos no (ex Twitter ) em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Argot Partners
Zenas@argotpartners.com


GLOBENEWSWIRE (Distribution ID 9059519)